UNIVERSITY OF CALIFORNIA, DAVIS
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1905-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.ucdavis.edu
Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department
- First Posted Date
- 2016-10-12
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 35
- Registration Number
- NCT02930941
- Locations
- 🇺🇸
University of California, Davis Medical Center, Sacramento, California, United States
Exercise Study Testing Enhanced Energetics of Mitochondria Video Integrated Delivery of Activity Training in CKD
Phase 2
Active, not recruiting
- Conditions
- Moderate-severe Chronic Kidney Disease Not Treated With DialysisDiabetic Kidney Disease, HgbA1c Less Than 8.5
- Interventions
- Behavioral: Combined Aerobic and Resistance Exercise via videoconferencing
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 32
- Registration Number
- NCT02923063
- Locations
- 🇺🇸
UC Davis Health, Sacramento, California, United States
Teledermatology and Modulation of Antibiotic Dose in Acne Vulgaris
Not Applicable
Completed
- Conditions
- Acne Vulgaris
- Interventions
- Other: Non Feedback groupOther: Feedback group
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 4
- Registration Number
- NCT02905851
- Locations
- 🇺🇸
UC Davis Department of Dermatology, Clinical Trials Unit, Sacramento, California, United States
Impact of Extra Virgin Olive Oil Oleocanthal Content on Platelet Reactivity
Not Applicable
Completed
- Conditions
- Cardiovascular Diseases
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 9
- Registration Number
- NCT02902913
Flumazenil for Hypoactive Delirium Secondary to Benzodiazepine Exposure
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 22
- Registration Number
- NCT02899156
- Locations
- 🇺🇸
UC Davis Medical Center, Sacramento, California, United States
Evaluation of the Roche Liat Flu/RSV Assay for Management of Influenza in the Emergency Department
Not Applicable
Completed
- Conditions
- Influenza, Human
- Interventions
- Diagnostic Test: ProcalcitoninOther: Pharmacist-Led Education
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 200
- Registration Number
- NCT02899065
- Locations
- 🇺🇸
University of California, Davis Medical Center, Sacramento, California, United States
Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
Phase 1
Completed
- Conditions
- Stage IV Renal Cell CancerMetastatic Renal Cell Cancer
- Interventions
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 31
- Registration Number
- NCT02899078
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Evidence-Based Tele-Emergency Network Grant Program
Not Applicable
Completed
- Conditions
- Critical Illness
- Interventions
- Other: TelemedicineOther: Telephone
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 696
- Registration Number
- NCT02877810
- Locations
- 🇺🇸
University of California, Davis, Medical Center, Sacramento, California, United States
Nexplanon and Combined Oral Contraceptive (COC) Combined Use Study
- First Posted Date
- 2016-08-02
- Last Posted Date
- 2018-12-28
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 20
- Registration Number
- NCT02852265
- Locations
- 🇺🇸
University of California, Davis, Sacramento, California, United States
Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase 2
Terminated
- Conditions
- Hormone-Resistant Prostate CancerStage IV Prostate Adenocarcinoma
- Interventions
- First Posted Date
- 2016-07-26
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 2
- Registration Number
- NCT02844582
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
© Copyright 2025. All Rights Reserved by MedPath